score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.2418	273.0	1.6e-05	0.0		Putatively Actionable	Dabrafenib + Trametinib	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Tafinlar [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2018.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/202806s008lbl.pdf	Putatively Actionable	Panitumumab	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0.0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	0				BRAF p.V600E (Missense)	1.0	MEL-IPI_Pat175	MEL-IPI_Pat175-Tumor-SM-7A15L	MEL-IPI_Pat175-Normal-SM-5VWIZ
Investigate Actionability - High	Preclinical		Clinical evidence	Somatic Variant	JAK1	Missense	p.A419V	0.0367	109.0	0.0	0.0		Investigate Actionability - High	PU-H71	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821							Investigate Actionability - Low	0.0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1	0				JAK1 p.A419V (Missense)		MEL-IPI_Pat175	MEL-IPI_Pat175-Tumor-SM-7A15L	MEL-IPI_Pat175-Normal-SM-5VWIZ
Investigate Actionability - High	Preclinical			Copy Number	CDKN2B	Deletion				0.0	0.0		Investigate Actionability - High	EPZ015666	Targeted therapy	These deletions are typically codeleted with MTAP, which has enhanced dependency on PRMT5 for which there is an inhibitor in clincial development	Kryukov GV, Wilson FH, Ruth JR, et al. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science. 2016;351(6278):1214-8.	https://doi.org/10.1126/science.aad5214												0				CDKN2B Deletion		MEL-IPI_Pat175	MEL-IPI_Pat175-Tumor-SM-7A15L	
Investigate Actionability - High	Preclinical			Copy Number	CDKN2A	Deletion				0.0	0.0		Investigate Actionability - High	EPZ015666	Targeted therapy	These deletions are typically codeleted with MTAP, which has enhanced dependency on PRMT5 for which there is an inhibitor in clincial development	Kryukov GV, Wilson FH, Ruth JR, et al. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science. 2016;351(6278):1214-8.	https://doi.org/10.1126/science.aad5214												0				CDKN2A Deletion		MEL-IPI_Pat175	MEL-IPI_Pat175-Tumor-SM-7A15L	
Investigate Actionability - Low	Inferential			Copy Number	CD274	Deletion				0.0	0.0		Investigate Actionability - Low	Pembrolizumab	Immunotherapy	PD-L1 expression in at least 50% of tumor cells correlated with improved efficacy of pembrolizumab in a trial of 495 patients with non-small cell lung cancer. 	Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018-28.	https://doi.org/10.1056/NEJMoa1501824												0				CD274 Deletion		MEL-IPI_Pat175	MEL-IPI_Pat175-Tumor-SM-7A15L	
Investigate Actionability - Low			Clinical evidence	Somatic Variant	EZH2	Missense	p.Y646H	0.2197	173.0	0.0	0.0														Investigate Actionability - Low	0.0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0				EZH2 p.Y646H (Missense)		MEL-IPI_Pat175	MEL-IPI_Pat175-Tumor-SM-7A15L	MEL-IPI_Pat175-Normal-SM-5VWIZ
Biologically Relevant				Somatic Variant	ESRP1	Missense	p.A122T	0.2247	89.0	0.0	0.0																			0				ESRP1 p.A122T (Missense)		MEL-IPI_Pat175	MEL-IPI_Pat175-Tumor-SM-7A15L	MEL-IPI_Pat175-Normal-SM-5VWIZ
Biologically Relevant				Copy Number	AKT3	Amplification				0.0	0.0																			0				AKT3 Amplification		MEL-IPI_Pat175	MEL-IPI_Pat175-Tumor-SM-7A15L	
Biologically Relevant				Copy Number	JAK2	Deletion				0.0	0.0																			0				JAK2 Deletion		MEL-IPI_Pat175	MEL-IPI_Pat175-Tumor-SM-7A15L	
Biologically Relevant				Mutational Signature	COSMIC Signature 1		0.294																							0				COSMIC Signature 1 (29%)		MEL-IPI_Pat175		
Biologically Relevant				Mutational Signature	COSMIC Signature 7		0.286																							0				COSMIC Signature 7 (29%)		MEL-IPI_Pat175		
